211 results
424B3
KZIA
Kazia Therapeutics Limited
19 Apr 24
Prospectus supplement
4:30pm
4.9 LITIGATION AND OTHER PROCEEDINGS. Except as disclosed in the SEC Documents, there are no material actions, suits, investigations, SEC inquiries … litigation resulting
therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting
6-K
EX-10.1
KZIA
Kazia Therapeutics Limited
19 Apr 24
Current report (foreign)
4:26pm
, no event has occurred that has had a Material Adverse Effect on the Company that has not been disclosed in the SEC Documents.
Section 4.9 LITIGATION … prejudiced by reason of such delay or failure), and (ii) permit the Indemnifying Party to assume the defense of such claim or any litigation resulting
424B3
KZIA
Kazia Therapeutics Limited
5 Feb 24
Prospectus supplement
4:19pm
contain statements that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation … , following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted against
F-1
KZIA
Kazia Therapeutics Limited
31 Jan 24
Registration statement (foreign)
12:00am
the meaning of the Private Securities Litigation Reform Act, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934 … action litigation has often been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs
F-3
KZIA
Kazia Therapeutics Limited
15 Dec 23
Shelf registration (foreign)
5:26pm
that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act, Section … of volatility in the market price of a company’s securities, securities class action litigation has often been instituted against that company
6-K
EX-10.1
6qozhdj0nbje
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
6-K
EX-99.1
wwxer aht
6 Dec 23
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
8:31am
424B5
asef9wmofi9uyq3fkj8
4 Dec 23
Prospectus supplement for primary offering
4:05pm
6-K
EX-99.1
fw4vr
1 Dec 23
Kazia Therapeutics Announces $2 Million Registered Direct Offering
8:30am
6-K
EX-99.1
v2x84ngo
5 Sep 23
Current report (foreign)
7:02am
6-K
EX-99.3
nir8yvk4
16 Nov 22
Current report (foreign)
7:24am
6-K
EX-99.1
hfazbd wo
15 Sep 22
Current report (foreign)
9:12am
6-K
ap8cws
23 Jun 22
Current report (foreign)
7:40am
6-K
EX-1.1
i93f0iawq2odjfo38md
22 Apr 22
Current report (foreign)
4:06pm
424B5
l2ld44
22 Apr 22
Prospectus supplement for primary offering
4:04pm
6-K
uuiooxpf15dr3 laj
10 Nov 21
Current report (foreign)
6:04am